270 related articles for article (PubMed ID: 35366313)
1. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.
Agrawal M; Petralia F; Tepler A; Durbin L; Reinisch W; Colombel JF; Shah SC
Inflamm Bowel Dis; 2023 Jan; 29(1):1-8. PubMed ID: 35366313
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
3. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.
Singh S; Proudfoot JA; Dulai PS; Jairath V; Fumery M; Xu R; Feagan BG; Sandborn WJ
Am J Gastroenterol; 2018 Aug; 113(8):1197-1205. PubMed ID: 29925913
[TBL] [Abstract][Full Text] [Related]
4. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
7. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials.
Singh S; Proudfoot J; Xu R; Sandborn WJ
Am J Gastroenterol; 2018 Jun; 113(6):883-889. PubMed ID: 29867171
[TBL] [Abstract][Full Text] [Related]
8. Racial Difference in Efficacy of Golimumab in Ulcerative Colitis.
Greywoode R; Petralia F; Ullman TA; Frederic Colombel J; Ungaro RC
Inflamm Bowel Dis; 2023 Jun; 29(6):843-849. PubMed ID: 35913121
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
11. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.
Singh S; Proudfoot J; Xu R; Sandborn WJ
Inflamm Bowel Dis; 2018 Sep; 24(10):2278-2284. PubMed ID: 29788260
[TBL] [Abstract][Full Text] [Related]
12. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.
Singh S; Proudfoot JA; Dulai PS; Xu R; Feagan BG; Sandborn WJ; Jairath V
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):424-431.e7. PubMed ID: 31108227
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
16. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
[TBL] [Abstract][Full Text] [Related]
18. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis.
Guo C; Wu K; Liang X; Liang Y; Li R
Pharmacol Res; 2019 Oct; 148():104455. PubMed ID: 31562896
[TBL] [Abstract][Full Text] [Related]
19. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Chande N; McDonald JW; Macdonald JK
Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
[TBL] [Abstract][Full Text] [Related]
20. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
